Q-Line Biotech IPO

IPO Details

• Open Date: 21 May 2026

• Close Date: 25 May 2026

• Minimum Investment: ₹2,74,400

• Lot Size: 400 shares

• Price Range: ₹326 to ₹343 per share

• Listing: NSE SME

• Issue Size: ₹214.48 Crore

• Listing Date: 29 May 2026

IPO Timeline

• Bidding Start: 21 May 2026

• Bidding Ends: 25 May 2026

• Allotment Finalisation: 26 May 2026

• Refund Initiation: 27 May 2026

• Demat Transfer: 27 May 2026

• Listing: 29 May 2026

About Q-Line Biotech Limited

Q-Line Biotech Limited, incorporated in 2010, is engaged in developing, manufacturing, and marketing diagnostic reagents, kits, point-of-care devices, and consumables, along with importing and distributing diagnostic equipment. The company serves hospitals, diagnostic laboratories, and medical colleges across India through direct sales and distributors. Its portfolio includes clinical chemistry, haematology, immunodiagnostics, molecular diagnostics, and pathology equipment. With strong in-house manufacturing capabilities and a focus on research and development, the company has established a wide distribution network and long-standing customer relationships in the healthcare diagnostics sector.

Q-Line Biotech Limited IPO Overview

Q-Line Biotech Limited IPO is a bookbuilding issue aggregating ₹214.48 crore, entirely comprising a fresh issue of 62,53,200 shares. The IPO opens on 21 May 2026 and closes on 25 May 2026. The allotment is expected to be finalised on 26 May 2026, followed by refunds and Demat transfers on 27 May 2026. The company is proposed to be listed on NSE SME on 29 May 2026. The price band is fixed at ₹326 to ₹343 per share, with a lot size of 400 shares. Hem Securities Ltd. is the lead manager, while Purva Sharegistry (India) Pvt. Ltd. is the registrar.

Q-Line Biotech Limited IPO Details

Particulars	Details
IPO Date	21 May 2026 to 25 May 2026
Listing Date	29 May 2026
Face Value	₹10 per share
Issue Price Band	₹326 to ₹343 per share
Lot Size	400 Shares
Total Issue Size	62,53,200 shares (aggregating up to ₹214.48 Cr)
Fresh Issue	62,53,200 shares (aggregating up to ₹214.48 Cr)
Offer for Sale	NA
Issue Type	Bookbuilding IPO
Listing At	NSE SME
Share Holding Pre Issue	1,70,74,999 shares
Share Holding Post Issue	2,33,28,199 shares
Market Maker Portion	3,13,200 shares

Q-Line Biotech Limited IPO Reservation

Investor Category	Shares Offered
QIB	Not more than 50% of the Net Issue
Retail	Not less than 35% of the Net Issue
NII (HNI)	Not less than 15% of the Net Issue

Q-Line Biotech Limited IPO Lot Size

Application	Lots	Shares	Amount
Retail (Min)	2	800	₹2,74,400
Retail (Max)	2	800	₹2,74,400
HNI (Min)	3	1,200	₹4,11,600

Q-Line Biotech Limited IPO Promoter Holding

Shareholding Status	Percentage
Pre-Issue	96.77%
Post-Issue	To be updated

Q-Line Biotech Limited IPO Valuation Overview

KPI	Value
Earnings Per Share (EPS)	23.57
Price/Earnings (P/E) Ratio	TBD
Return on Net Worth (RoNW)	16.88%
Net Asset Value (NAV)	140.81
Return on Equity	16.88%
Return on Capital Employed (ROCE)	13.32%
EBITDA Margin	27.64%
PAT Margin	16.65%
Debt to Equity Ratio	1.06

Objectives of the Proceeds

• Meeting working capital requirements to support business expansion – ₹93.50 Cr

• Repayment of existing borrowings partially or fully – ₹90.00 Cr

• Funding general corporate purposes and strategic initiatives

Key Financials (in ₹ crore)

Particulars	31 Dec 2025	31 Mar 2025	31 Mar 2024	31 Mar 2023
Assets	561.34	455.49	339.25	251.58
Revenue	236.50	322.58	206.45	184.81
Profit After Tax	38.69	28.13	34.44	32.10
Reserves and Surplus	212.89	188.37	160.24	125.79
Total Borrowings	243.85	164.95	96.91	73.65

SWOT Analysis of Q-Line Biotech Limited

Strengths and Opportunities	Weaknesses and Threats
Diversified diagnostics portfolio across multiple healthcare segments	High borrowing levels may pressure future profitability
Strong manufacturing and R&D capabilities support innovation	Competitive diagnostics market with pricing pressures
Wide distribution network across major Indian regions	Regulatory changes may affect compliance costs
Growing demand for diagnostic solutions boosts expansion potential	Dependence on healthcare sector procurement cycles

IPO Strengths

• Established manufacturing capabilities with strong R&D and quality control

• Diversified product portfolio focused on diagnostic healthcare solutions

• Widespread distribution network across all four Indian regions

• Long-standing customer relationships with hospitals and laboratories

• Experienced promoters and management team with industry expertise

Peer Group Comparison

As per the DRHP, there are no comparable listed peer details provided for the company.